Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p87
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 87/312)
Character Range: 16011474–16020053

site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.
C15025              P15025         CN15025          Desmopressin                                                           Primary nocturnal enuresis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            Compliance with Authority Required procedures - Streamlined Authority Code 15025
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient;
                                                                                                                           Patient must be 6 years of age or older;
                                                                                                                           Patient must be one in whom an enuresis alarm is contraindicated.
C15028              P15028         CN15028          Bromocriptine                                                          Parkinson disease
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
C15030              P15030         CN15030          Medroxyprogesterone                                                    Endometriosis
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient.
C15031              P15031         CN15031          Exemestane                                                             Metastatic (Stage IV) breast cancer
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           The condition must be hormone receptor positive; AND
                                                                                                                           The condition must be human epidermal growth factor receptor 2 (HER2) negative; AND
                                                                                                                           Patient must be receiving PBS-subsidised everolimus concomitantly for this condition;
                                                                                                                           Patient must not be pre-menopausal.
C15032              P15032         CN15032          Alendronic acid with colecalciferol                                    Corticosteroid-induced osteoporosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Compliance with Authority Required procedures - Streamlined Authority Code 15032
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           Patient must currently be on long-term (at least 3 months), high-dose (at least 7.5 mg per day prednisolone or equivalent) corticosteroid therapy; AND
                                                                                                                           Patient must have a Bone Mineral Density (BMD) T-score of -1.5 or less; AND
                                                                                                                           Patient must not receive concomitant treatment with any other PBS-subsidised anti-resorptive agent for this condition.
                                                                                                                           The duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated.
C15035              P15035         CN15035          Alendronic acid with colecalciferol                                    Established osteoporosis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              Compliance with Authority Required procedures - Streamlined Authority Code 15035
                                                                                                                           The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient; AND
                                                                                                                           Patient must have fracture due to minimal trauma; AND
                                                                                                                           Patient must not receive concomitant treatment with any other PBS-subsidised anti-resorptive agent for this condition.
                                                                                                                           The fracture must have been demonstrated radiologically and the year of plain x-ray or computed tomography (CT) scan or magnetic resonance imaging (MRI) scan must be documented in the patient's medical records when treatment is initiated.
                                                                                                                           A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or